IMPACT COMPARISON OF ADJUVANT AND NEOADJUVANT CHEMOTHERAPY FOR THE BREAST CANCER TREATMENT.

INABA, L. A. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), BASTOS, E. A. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), RODRIGUES, F. F. O. (Instituto do Câncer Dr. Arnaldo Vieira de Carvalho), SILVA, R. M. (Instituto do Câncer Dr. Arnaldo

Instituto do Câncer Dr. Arnaldo Vieira de Carvalho (ICAVC)To evaluate the impact of adjuvant and neoadjuvant therapies concerning overall survival (OS) and disease-free survival (DFS) in patients with breast cancer. A retrospective database analysis from our service in patients with breast cancer treated at our institution (ICAVC) during 08/31/2006 and 01/10/2010 with follow up until 01/12/2016. A total of 106 patients with invasive breast cancer SOE were included in the study, and 32 (30,2%) received neoadjuvant chemotherapy based on anthracycline and taxane. We observed that in the group of patients submitted to neoadjuvant therapy, two (6.2%) died, nine (28%) had distant metastases, and one (3%) had a local recurrence. In patients submitted to the adjuvant regimen, we observed six (8%) of deaths, 12 (16.2%) of distant metastases and four (5.4%) of local recurrences. When we analyzed the Kaplan-Meier curves of our cohort, we notice that patients submitted to neoadjuvant chemotherapy had a global survival slightly larger than adjuvant chemotherapy, but there was no statistical difference between the groups. Both neoadjuvant and adjuvant chemotherapy treatment scenarios presented a tendency that suggests an equivalence concerning OS and DFS.breast cancer, neoadjuvant chemotherapy, overall survival

Return